2023 World Conference on Lung Cancer (Posters)-EP13.01. Prognostic Impact of Neutrophil-to-Lymphocyte Ratio (NLR) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

EP13.01. Prognostic Impact of Neutrophil-to-Lymphocyte Ratio (NLR) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the prognostic impact of the neutrophil-to-lymphocyte ratio (NLR) for patients with extensive-stage small cell lung cancer (ES-SCLC) treated with immune checkpoint inhibitors (ICIs). The authors retrospectively examined the change in NLR during treatment and evaluated its potential as a biomarker for time to treatment failure (TTF) and overall survival (OS). They also assessed the relationship between the efficacy of immunochemotherapy and NLR.<br /><br />The study included 152 ES-SCLC patients who received first-line chemotherapy between 2008 and 2022. NLR values were measured at the start of each-line chemotherapy and at the end of treatment or death. The patients were divided into NLR1-low (NLR ≤ 5) and NLR1-high (NLR > 5) subgroups. The median survival time (MST) for the NLR1-low group was 12.8 months, compared to 5.4 months for the NLR1-high group. In a multivariate analysis, elevated NLR1 was an independent factor for worse OS. Additionally, the prognosis was worse for patients with high NLR1 and NLR2 (NLR > 5) compared to those with low NLR1 and NLR2.<br /><br />The study also found that in the NLR1-low group, immune chemotherapy was associated with longer MST compared to cytotoxic chemotherapy alone. Furthermore, within the immune chemotherapy subgroup, lower NLR was associated with longer OS.<br /><br />In conclusion, NLR and its change during treatment may serve as prognostic predictors for ES-SCLC patients. The authors suggest that NLR at the start of first-line chemotherapy could be helpful in determining the addition of ICIs. These findings highlight the potential of NLR as a useful biomarker for patient selection and treatment decisions in ES-SCLC.

Asset Subtitle

Masashi Ishihara

Meta Tag

Speaker Masashi Ishihara

Topic SCLC & Neuroendocrine Tumors: Biomarkers & Radiomics

Keywords

neutrophil-to-lymphocyte ratio

NLR

extensive-stage small cell lung cancer

ES-SCLC

immune checkpoint inhibitors

prognostic impact

time to treatment failure

overall survival

immunochemotherapy

chemotherapy